RU94046067A - Замещенные 1,2,3,4-тетрагидроизохинолины, промежуточные продукты, фармкомпозиция и способ лечения - Google Patents
Замещенные 1,2,3,4-тетрагидроизохинолины, промежуточные продукты, фармкомпозиция и способ леченияInfo
- Publication number
- RU94046067A RU94046067A RU94046067/04A RU94046067A RU94046067A RU 94046067 A RU94046067 A RU 94046067A RU 94046067/04 A RU94046067/04 A RU 94046067/04A RU 94046067 A RU94046067 A RU 94046067A RU 94046067 A RU94046067 A RU 94046067A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- tetrahydroisoquinolines
- substituted
- intermediate compounds
- pharmcomposition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Изобретение относится к новым замещенным 1,2,3,4-тетрагидроизохинолинам, которые являются полезными при лечении сосудистого рестиноза, различных нарушений центральной нервной системы, в регулировании женских репродуктивных функций, в усилении познавательной способности, атеросклероза и при лечении нарушений избыточной АVР секреции. Новые промежуточные соединения, используемые при получении соединений, также представлены в предлагаемом изобретении. Представлены также способы использования соединений и фармацевтических композиций, содержащих их.
Claims (1)
- Изобретение относится к новым замещенным 1,2,3,4-тетрагидроизохинолинам, которые являются полезными при лечении сосудистого рестиноза, различных нарушений центральной нервной системы, в регулировании женских репродуктивных функций, в усилении познавательной способности, атеросклероза и при лечении нарушений избыточной АVР секреции. Новые промежуточные соединения, используемые при получении соединений, также представлены в предлагаемом изобретении. Представлены также способы использования соединений и фармацевтических композиций, содержащих их.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US885.263 | 1992-05-19 | ||
US07/885,263 US5246943A (en) | 1992-05-19 | 1992-05-19 | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
US885263 | 1992-05-19 | ||
PCT/US1993/003662 WO1993023378A1 (en) | 1992-05-19 | 1993-04-19 | Substituted 1,2,3,4-tetrahydroisoquinolines with angiotensin ii receptor antagonist properties |
Publications (2)
Publication Number | Publication Date |
---|---|
RU94046067A true RU94046067A (ru) | 1996-09-27 |
RU2135473C1 RU2135473C1 (ru) | 1999-08-27 |
Family
ID=25386509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94046067A RU2135473C1 (ru) | 1992-05-19 | 1993-04-19 | Замещенные 1,2,3,4-тетрагидроизохинолины, промежуточные продукты и фармкомпозиция |
Country Status (14)
Country | Link |
---|---|
US (4) | US5246943A (ru) |
EP (1) | EP0641326A1 (ru) |
JP (1) | JPH07508266A (ru) |
KR (1) | KR950701622A (ru) |
AU (2) | AU671283B2 (ru) |
CA (1) | CA2134765A1 (ru) |
CZ (1) | CZ284177B6 (ru) |
HU (1) | HU217069B (ru) |
MX (1) | MX9302888A (ru) |
NO (1) | NO302071B1 (ru) |
NZ (1) | NZ252856A (ru) |
RU (1) | RU2135473C1 (ru) |
SK (1) | SK280677B6 (ru) |
WO (1) | WO1993023378A1 (ru) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
US5409926A (en) * | 1993-07-19 | 1995-04-25 | Merck & Co., Inc. | AT-2 antagonist inhibition of vascular restenosis |
US5464854A (en) * | 1993-11-11 | 1995-11-07 | Depadova; Anathony S. | Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S. |
US5658943A (en) * | 1995-01-05 | 1997-08-19 | Warner-Lambert Company | Phenylalanine derivatives as endothelin antagonists |
DK0832069T3 (da) * | 1995-06-07 | 2003-04-22 | Pfizer | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) |
WO1996040255A2 (en) * | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist |
JP2000515133A (ja) | 1996-07-01 | 2000-11-14 | イーライ・リリー・アンド・カンパニー | 血糖降下性および脂質低下性の化合物 |
ATE277907T1 (de) * | 1996-07-01 | 2004-10-15 | Lilly Co Eli | Blutzuckersenkende und lipidsenkende verbindungen |
US5912342A (en) * | 1997-08-12 | 1999-06-15 | Heinonen; Petri | Compounds a containing a solid support |
AU9512298A (en) * | 1997-09-30 | 1999-04-23 | Molecular Design International, Inc. | Beta3-adrenoreceptor agonists, agonist compositions and methods of using |
US5955471A (en) * | 1998-01-13 | 1999-09-21 | Sk Corporation | Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same |
US6180625B1 (en) | 1998-03-24 | 2001-01-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
US6437006B1 (en) | 1999-09-27 | 2002-08-20 | American Cyanamid Company | Pharmaceutical carrier formulation |
CA2393265A1 (en) | 1999-12-03 | 2001-06-07 | Kyoto Pharmaceutical Industries, Ltd. | Novel heterocyclic compounds and salts thereof and medicinal use of the same |
PE20020506A1 (es) * | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
US6593341B2 (en) | 2001-03-29 | 2003-07-15 | Molecular Design International, Inc. | β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same |
CZ20033415A3 (cs) | 2001-05-29 | 2004-06-16 | Kyoto Pharmaceutical Industries, Ltd. | Nové heterocyklické deriváty a jejich lékařské použití |
YU94003A (sh) * | 2001-05-29 | 2006-08-17 | Kyoto Pharmaceutical Industries Ltd. | Novo heterociklično jedinjenje i njegova medicinska upotreba |
US7226928B2 (en) * | 2001-06-15 | 2007-06-05 | 3M Innovative Properties Company | Methods for the treatment of periodontal disease |
GB0124933D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124941D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124938D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124936D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124939D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
GB0124934D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
CA2474192C (en) * | 2002-02-12 | 2011-06-21 | Smithkline Beecham Corporation | Nicotinamide derivates useful as p38 inhibitors |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
US6596734B1 (en) | 2002-10-11 | 2003-07-22 | Molecular Design International, Inc. | Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists |
WO2004050628A1 (en) * | 2002-12-02 | 2004-06-17 | Pharmacia & Upjohn Company Llc | The use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence |
GB0308185D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308186D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0308201D0 (en) * | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
GB0402143D0 (en) * | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
US20080051416A1 (en) * | 2004-10-05 | 2008-02-28 | Smithkline Beecham Corporation | Novel Compounds |
WO2006055951A2 (en) * | 2004-11-19 | 2006-05-26 | Portola Pharmaceuticals, Inc. | Tetrahydroisoquinolines as factor xa inhibitors |
SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
AU2005318882B2 (en) * | 2004-12-24 | 2011-04-21 | Novartis Ag | Method of treatment or prophylaxis |
EP2650011A1 (en) * | 2004-12-24 | 2013-10-16 | Spinifex Pharmaceuticals Pty Ltd | Method of treatment or prophylaxis |
JP2008534504A (ja) * | 2005-03-22 | 2008-08-28 | アゼヴァン ファーマスーティカルズ,インコーポレイテッド | 月経前障害を治療するためのβラクタミルアルカン酸 |
GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
AU2007229322B2 (en) * | 2006-03-20 | 2012-04-05 | Novartis Ag | Method of treatment or prophylaxis inflammatory pain |
TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
US9095587B2 (en) | 2010-01-19 | 2015-08-04 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
US9376424B2 (en) | 2010-07-01 | 2016-06-28 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
WO2012010843A1 (en) * | 2010-07-21 | 2012-01-26 | Spinifex Pharmaceuticals Pty Ltd | Salt and solvates of a tetrahydroisoquinoline derivative |
EP2420237A1 (en) * | 2010-08-11 | 2012-02-22 | Ville Takio | Fluorinated derivatives of endogenous isoquinolines for use in the treatment of diseases mediated through endogenous isoquinoline pathways |
JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
NZ630908A (en) * | 2013-07-08 | 2017-08-25 | Novartis Ag | Heterocyclic compounds and methods of their use |
JP7255967B2 (ja) | 2014-03-28 | 2023-04-11 | アゼヴァン ファーマスーティカルズ,インコーポレイテッド | 神経変性疾患を治療するための組成物および方法 |
CN106478502B (zh) * | 2015-08-29 | 2021-04-27 | 上海翰森生物医药科技有限公司 | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
CN106831573B (zh) * | 2017-01-23 | 2019-05-24 | 南阳师范学院 | (n-1,2,3,4-四氢异喹啉基)-阿魏酰胺化合物、制备方法及其应用 |
WO2018172950A1 (en) | 2017-03-23 | 2018-09-27 | Novartis Ag | Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate |
CN110914243B (zh) * | 2017-06-09 | 2023-02-28 | 山东丹红制药有限公司 | 作为at2r受体拮抗剂的羧酸衍生物 |
BR112020005107A2 (pt) | 2017-09-15 | 2020-11-03 | Azevan Pharmaceuticals, Inc. | composições e métodos para o tratamento de lesão cerebral |
CN112313222B (zh) * | 2018-06-19 | 2024-01-26 | 浙江海正药业股份有限公司 | 四氢异喹啉类衍生物、其制备方法及其用途 |
EP3820833A4 (en) * | 2018-07-12 | 2022-08-03 | Codexis, Inc. | MODIFIED AMMONIA-LYASE PHENYLALANINE POLYPEPTIDES |
WO2020012266A1 (en) | 2018-07-12 | 2020-01-16 | Novartis Ag | Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase |
CN111620816B (zh) * | 2020-05-27 | 2023-06-02 | 上海赛默罗生物科技有限公司 | 螺桨烷类衍生物、其制备方法、药物组合物和用途 |
CN113880825A (zh) | 2020-07-01 | 2022-01-04 | 浙江海正药业股份有限公司 | 四氢异喹啉类衍生物的盐、其制备方法及其医药应用 |
CN111777555B (zh) * | 2020-09-04 | 2020-12-01 | 上海赛默罗生物科技有限公司 | 脂肪环烷衍生物、其制备方法、药物组合物和其应用 |
CN114315619B (zh) * | 2022-01-17 | 2023-03-24 | 山东泓瑞医药科技股份公司 | 一种二甲氧基多巴的合成方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3063420D1 (en) * | 1979-03-26 | 1983-07-07 | Takeda Chemical Industries Ltd | Tetrahydroisoquinolines, their production and the compounds and pharmaceutical compositions containing them for use in the prevention or treatment of hypertension |
GB2048863B (en) * | 1979-05-16 | 1983-06-15 | Morton Norwich Products Inc | Tetrahydroisoquinoline-3-carboxylic acids |
US4344949A (en) * | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
IN156096B (ru) * | 1981-03-19 | 1985-05-11 | Usv Pharma Corp | |
FR2595356B1 (fr) * | 1986-03-05 | 1991-05-24 | Pasteur Strasbourg Universite | Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications |
US4812462A (en) * | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
GB8807922D0 (en) * | 1988-04-05 | 1988-05-05 | Fujisawa Pharmaceutical Co | Isoquinoline compound & process for preparation thereof |
US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
-
1992
- 1992-05-19 US US07/885,263 patent/US5246943A/en not_active Expired - Lifetime
-
1993
- 1993-04-19 NZ NZ252856A patent/NZ252856A/xx unknown
- 1993-04-19 CA CA002134765A patent/CA2134765A1/en not_active Abandoned
- 1993-04-19 SK SK1385-94A patent/SK280677B6/sk unknown
- 1993-04-19 JP JP5520231A patent/JPH07508266A/ja active Pending
- 1993-04-19 RU RU94046067A patent/RU2135473C1/ru active
- 1993-04-19 AU AU42906/93A patent/AU671283B2/en not_active Ceased
- 1993-04-19 CZ CZ942828A patent/CZ284177B6/cs not_active IP Right Cessation
- 1993-04-19 EP EP93912313A patent/EP0641326A1/en not_active Withdrawn
- 1993-04-19 WO PCT/US1993/003662 patent/WO1993023378A1/en not_active Application Discontinuation
- 1993-04-19 HU HU9403322A patent/HU217069B/hu not_active IP Right Cessation
- 1993-04-19 KR KR1019940704151A patent/KR950701622A/ko not_active IP Right Cessation
- 1993-05-18 MX MX9302888A patent/MX9302888A/es not_active IP Right Cessation
- 1993-06-11 US US08/075,973 patent/US5350757A/en not_active Expired - Fee Related
-
1994
- 1994-04-28 US US08/234,759 patent/US5489686A/en not_active Expired - Fee Related
- 1994-11-18 NO NO944421A patent/NO302071B1/no not_active IP Right Cessation
-
1995
- 1995-07-31 US US08/509,473 patent/US5525614A/en not_active Expired - Fee Related
-
1996
- 1996-09-13 AU AU65623/96A patent/AU682136B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
MX9302888A (es) | 1993-11-01 |
SK138594A3 (en) | 1995-07-11 |
CA2134765A1 (en) | 1993-11-25 |
RU2135473C1 (ru) | 1999-08-27 |
KR950701622A (ko) | 1995-04-28 |
US5246943A (en) | 1993-09-21 |
WO1993023378A1 (en) | 1993-11-25 |
AU671283B2 (en) | 1996-08-22 |
AU682136B2 (en) | 1997-09-18 |
NO944421D0 (no) | 1994-11-18 |
NO302071B1 (no) | 1998-01-19 |
US5489686A (en) | 1996-02-06 |
CZ282894A3 (en) | 1995-09-13 |
NO944421L (no) | 1994-11-18 |
AU6562396A (en) | 1996-11-07 |
HU9403322D0 (en) | 1995-02-28 |
NZ252856A (en) | 1997-08-22 |
HUT70441A (en) | 1995-10-30 |
US5350757A (en) | 1994-09-27 |
US5525614A (en) | 1996-06-11 |
EP0641326A1 (en) | 1995-03-08 |
AU4290693A (en) | 1993-12-13 |
JPH07508266A (ja) | 1995-09-14 |
HU217069B (hu) | 1999-11-29 |
CZ284177B6 (cs) | 1998-09-16 |
SK280677B6 (sk) | 2000-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU94046067A (ru) | Замещенные 1,2,3,4-тетрагидроизохинолины, промежуточные продукты, фармкомпозиция и способ лечения | |
CA2134964A1 (en) | Bridged Aza-Bicyclic Derivatives as Substance P Antagonists | |
IL72120A (en) | 2-pyrimidinyl-1-piperazine derivatives,their preparation and pharmaceutical compositions containing them | |
AU5169693A (en) | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists | |
HU9303666D0 (en) | Azanorbornane derivatives | |
HUT67434A (en) | Fluoroalkoxy-benzylamino derivatives of nitrogen containing heterocycles and pharmaceutical compositions containing them and process for their production | |
CA2141048A1 (en) | Substituted benzylamino nitrogen containing non-aromatic heterocycles | |
RU94038064A (ru) | Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция | |
CA2104909A1 (en) | Decahydroisoquinolines as excitatory amino acid receptor antagonists | |
DE69427704T2 (de) | Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane | |
ATE223912T1 (de) | Pyridylalkan-säureamide als cytostatika und immunosupressive arzneimittel | |
MY120976A (en) | 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines | |
RU94036749A (ru) | Замещенные 1-нафтилпиразол-3-карбоксамиды, способ их получения, содержащие их фармацевтические композиции и промежуточные соединения синтеза | |
MX9403088A (es) | Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso. | |
YU15895A (sh) | 5-vinil i 5-etinil-hinolon karbonske kiseline postupci za njihovo pripremanje kao i njihova upotreba za pripremanje lekova | |
HU9602413D0 (en) | Novel tetrasubstituted imidazole derivatives, method for preparing same, resulting novel intermediates, use thereof as drugs, and pharmaceutical compositions containing same | |
BR9803385A (pt) | AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas. | |
PL328225A1 (en) | Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors | |
BG102080A (en) | Amino acid derivatives of substituted quinoxalin 2,3-dion derivatives such as glutamate receptor antagonists | |
BG101929A (en) | Benzamides for neurodegenerative disorder treatment | |
GB9116056D0 (en) | Compounds | |
NZ320522A (en) | Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the compounds | |
IL115004A (en) | Pharmaceutical compositions containing substituted 6-amino-4H-pyrans certain novel such compounds and their preparation | |
TW367320B (en) | Novel aryl compounds having CNS activity, process for their preparation and their use as medicaments | |
RU94035756A (ru) | Производные имидазола, являющиеся ингибиторами питокинов, способы их получения, фармацевтическая композиция |